This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining more than 1% on Friday.Shares of Roku Inc (NASDAQ:ROKU) fell sharply in pre-market trading following third-quarter results.Roku reported third-quarter net revenue of $1.211 billion, up 14% year-over-year. The revenue total beat a Street consensus estimate of $1.206 billon, according to data from Benzinga Pro. The company reported third-quarter platform revenue of $1.06 billion, up 17% year-over-year and devices revenue of $1 ...

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining more than 1% on Friday.Shares of Roku Inc (NASDAQ:ROKU) fell sharply in pre-market trading following third-quarter results.Roku reported third-quarter net revenue of $1.211 billion, up 14% year-over-year. The revenue total beat a Street consensus estimate of $1.206 billon, according to data from Benzinga Pro. The company reported third-quarter platform revenue of $1.06 billion, up 17% year-over-year and devices revenue of $1 ...

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total ...

PresentationYuval CohenCEO & Director Good morning, everyone. Thank you so much for coming here this morning. We know how busy everybody is. So it's really wonderful to see. That's a wonderfully full room. So thank you for that. I just want to start by some quick thank yous. First of all, thank you to the audience for coming here. Thank you to our panel for taking the time from their very busy schedule to spend an hour with us today talking about our data, especially around head and neck. Very big thank yo ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Connecting Innovation to Purpose Corporate Presentation October 19, 2025 www.corbuspharma.com @corbuspharma NASDAQ: CRBP 1 Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opp ...

Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) Update / Briefing October 19, 2025 04:00 AM ET Speaker0Good morning, everyone. Thank you so much for coming here this morning. We know how busy everybody is, so it's really wonderful to see. That's a wonderfully full room, so thank you for that. I just want to start by some quick thank yous.First of all, thank you to the audience for coming here. Thank you to our panel for taking the time from their very busy schedule to spend an hour with us today talking abo ...

3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in mid-2026Company to host an HNSCC KOL event during ESMO25 NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a poster at the 202 ...

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 abstract for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster during ESMO. Th ...